Design and analysis of unit cost estimation studies: How many hospital diagnoses? How many countries?
- 8 August 2002
- journal article
- review article
- Published by Wiley in Health Economics
- Vol. 12 (7) , 517-527
- https://doi.org/10.1002/hec.750
Abstract
We evaluated three questions that commonly arise when unit costing exercises for multinational trials are conducted: (1) In countries where investigators plan to collect hospital unit cost estimates for a selected set of diagnoses, how should one estimate unit costs for the remaining diagnoses observed in the trial for which cost data were not collected? (2) For how many hospital diagnoses should estimates be obtained? (3) For how many countries should they be obtained? We addressed these questions using unit cost data collected in four western European countries and three relative value measures from the US Medicare diagnosis‐related group (DRG) payment system. We found that the arithmetic mean length of stay from the US DRG payment system was a good predictor of unit costs in four countries in Europe. We also found that the imputation error decreased as the number of hospital diagnoses and countries sampled increased, but that the rate of reduction in error shrank. Finally, we found that – given the existence of a reliable method for cost imputation – from a pure information standpoint, it is better to obtain estimates for fewer hospital diagnoses from more countries than the reverse. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATIONTransplantation, 2000
- Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal TransplantationPharmacoEconomics, 2000
- Cost effectiveness of zanamivir for the treatment of influenza in a high risk population in Australia.PharmacoEconomics, 2000
- Hospital Selection for Unit Cost Estimates in Multicentre Economic EvaluationsPharmacoEconomics, 1999
- Resource costing for multinational neurologic clinical trials: methods and resultsHealth Economics, 1998
- Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplantation for Hodgkin’s and non-Hodgkin’s lymphomaBone Marrow Transplantation, 1998
- Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart DiseaseNew England Journal of Medicine, 1997
- Results of the Economic Evaluation of the FIRST Study:A Multinational Prospective Economic EvaluationInternational Journal of Technology Assessment in Health Care, 1996
- Costs and effects of enalapril therapy in patients with symptomatic heart failure: An economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trialJournal of Cardiac Failure, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995